Back to Dashboard
COGT · Healthcare

COGENT BIOSCIENCES INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Weak — few signals

No standout activity across the feeds we track.

Hedge funds
40
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Limited info. COGENT BIOSCIENCES INC is not currently in our model portfolio, but 7 tracked investors hold it. We're showing what we know from their latest 13F filings.
Market cap
$6.7B
Industry
Biotechnology
Exchange
NasdaqGS
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor…
7
Investors
1
New positions
4
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Tudor Investment (Paul Tudor Jones)
Trust weight: 1.2×
New position
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Duquesne Family Office (Druckenmiller)
Trust weight: 1.6×
Increased +109%
% of portfolio
1.9%
Position change
+109%
1.9% of Duquesne Family Office's portfolio
D.E. Shaw & Co
Trust weight: 1.0×
Increased +47%
% of portfolio
0.1%
Position change
+47%
0.1% of D.E. Shaw & Co's portfolio
Millennium Management (Englander)
Trust weight: 1.0×
Increased +191%
% of portfolio
0.0%
Position change
+191%
0.0% of Millennium Management's portfolio
AQR Capital Management
Trust weight: 1.0×
Increased +4%
% of portfolio
0.0%
Position change
+4%
0.0% of AQR Capital Management's portfolio
Point72 (Steve Cohen)
Trust weight: 1.1×
Decreased −33%
% of portfolio
0.1%
Position change
−33%
0.1% of Point72's portfolio
Citadel Advisors
Trust weight: 1.0×
Decreased −14%
% of portfolio
0.0%
Position change
−14%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to COGENT BIOSCIENCES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell COGENT BIOSCIENCES INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime
© 2026 Bogen Capital  ·  Not financial advice  ·  Data delayed up to 135 days Methodology  ·  Contact  ·  API